A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521353-16-00

Enrollment

Registered

2026-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Angioedema

Brief summary

Incidence and severity of TEAEs.

Detailed description

The time-normalized number of Investigator-confirmed HAE attacks (per month), The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy (per month), The -normalized number of moderate or severe Investigator confirmed HAE attacks (per month), The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free)

Interventions

DRUGSterile normal saline (0.9% sodium chloride solution)

DRUGADX-324

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of TEAEs.	—

Secondary

Measure	Time frame
The time-normalized number of Investigator-confirmed HAE attacks (per month), The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy (per month), The -normalized number of moderate or severe Investigator confirmed HAE attacks (per month), The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 25, 2026